Source: International Congress 2019 – Understanding, monitoring and targeting severe asthma
Disease area: Airway diseases



Rating:

Share or cite this content

Citations should be made in the following way:
F. Bini (Garbagnate Milanese, Italy), D. Visca (Tradate, Italy), N. Grassi (Garbagnate Milanese, Italy), A. De Lauretis (Garbagnate Milanese, Italy), A. Spanevello (Tradate, Italy), A. Vaghi (Garbagnate Milanese, Italy). Retrospective study on the combined use of voriconazole and prednisolone in the treatment of acute allergic bronchopulmonary aspergillosis (ABPA).. 545

Member's Comments

No comment yet.

Related content which might interest you: A randomised trial of voriconazole and prednisolone monotherapy in acute-stage allergic bronchopulmonary aspergillosis complicating asthma Source: Eur Respir J, 52 (3) 1801159; 10.1183/13993003.01159-2018 Year: 2018 Follow-up of patients with allergic bronchopulmonary aspergillosis (ABPA) - side effects of long-term therapy Source: Eur Respir J 2003; 22: Suppl. 45, 237s Year: 2003 Effect of itraconazole therapy on disease course in 3 cases of allergic bronchopulmonary mycosis presented as refractory asthma Source: Annual Congress 2008 - Allergy and immunology of asthma and beyond Year: 2008 Itraconazole and allergic bronchopulmonary aspergillosis: long-term follow-up Source: Eur Respir J 2001; 18: Suppl. 33, 432s Year: 2001 Omalizumab in patients with allergic bronchopulmonary aspergillosis (ABPA): a multicenter case series study in Spain Source: Annual Congress 2009 - Persistent asthma: still an uncontrolled disease requiring new treatments strategies in 2009 Year: 2009 Omalizumab and voriconazole in allergic broncopulmonary aspergillosis (A case series) Source: Annual Congress 2011 - Allergen immunotherapy and anti-immunoglobulin E Year: 2011 Complex treatment of allergic bronchopulmonary aspergillosis (ABPA) in asthmatic patient including anti-IgE therapy – A case report Source: Annual Congress 2012 - Phenotypes and mechanisms of treatment of asthma Year: 2012 A randomised trial of glucocorticoids in acute-stage allergic bronchopulmonary aspergillosis complicating asthma Source: Eur Respir J 2016; 47: 490-498 Year: 2016 Treatment options in severe fungal asthma and allergic bronchopulmonary aspergillosis Source: Eur Respir J 2014; 43: 1487-1500 Year: 2014 Clinical presentation in 12 patients with allergic bronchopulmonary aspergillosis Source: Annual Congress 2007 - Primary care respiratory problems Year: 2007 Pulse methylprednisolone in allergic bronchopulmonary aspergillosis exacerbations Source: Eur Respir Rev 2014; 23: 149-152 Year: 2014 Improvement in asthma severity and control by voriconazole and posaconazole in severe asthma with fungal sensitization (SAFS) and ABPA Source: Annual Congress 2012 - Exacerbations of asthma and COPD: assessment, impact and novel treatments Year: 2012 Effects and side effects of long term steroid therapy of allergic bronchopulmonary aspergillosis (ABPA) in cystic fibrosis Source: Annual Congress 2010 - Cystic fibrosis: lung disease infection and more Year: 2010 Place of azoles in the treatment of allergic bronchopulmonary candidiasis Source: Eur Respir J 2006; 28: Suppl. 50, 52s Year: 2006 Concurrent allergic bronchopulmonary aspergillosis and aspergilloma: is it a more severe form of the disease? Source: Eur Respir Rev 2010 19: 261-263 Year: 2010 Treatment of chronic necrotizing pulmonary aspergillosis (CNPA) with micafungin (MCFG) Source: Eur Respir J 2005; 26: Suppl. 49, 410s Year: 2005 Clinical characteristics and outcome of patients with allergic bronchopulmonary aspergillosis Source: International Congress 2017 – Many faces of asthma and allergies Year: 2017 Iatrogenic adrenal insufficiency as a side-effect of combined treatment of itraconazole and budesonide Source: Eur Respir J 2002; 20: 127-133 Year: 2002 Serum level directed itraconazole therapy in allergic bronchopulmonary aspergillosis Source: International Congress 2016 – Molecular immunology of the lung Year: 2016 Prolonged oral corticosteroid therapy in allergic bronchopulmonary aspergillosis (ABPA) treatment does not increase pseudomonas aeruginosa risk Source: International Congress 2015 – Cystic fibrosis: microbiology, immunology and assessment Year: 2015